Last update 16 May 2024

Citalopram Hydrobromide

Last update 16 May 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryCitalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines. Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. The antidepressant effects may take one to four weeks to occur. It is taken by mouth. Common side effects include nausea, trouble sleeping, sexual problems, shakiness, feeling tired, and sweating. Serious side effects include an increased risk of suicide in those under the age of 25, serotonin syndrome, glaucoma, and QT prolongation. Antidepressant discontinuation syndrome or persistent Post-SSRI sexual dysfunction may occur when stopped.

Drug Type

Small molecule drug

Synonyms

Citalopram hydrobromide (USP)

+ [17]

Target

SERT

Mechanism

SERT inhibitors(Serotonin transporter inhibitors)

Therapeutic Areas

Other Diseases

Active Indication

Depressive Disorder, MajorDepressive Disorder

Inactive Indication-

Originator Organization

H. Lundbeck A/S

Active Organization

AbbVie, Inc.Biovail Laboratories International SRLALMATICA PHARMA INC

+ [1]

Inactive Organization

Kalaco Scientific, Inc.

Drug Highest PhaseApproved

First Approval Date

DK (01 Jan 1989),

Depressive Disorder

Regulation-

Structure

Molecular FormulaC20H21FN2O

InChIKeyWSEQXVZVJXJVFP-UHFFFAOYSA-N

CAS Registry59729-33-8

View All Structures (2)

Clinical Trials associated with Citalopram Hydrobromide

NCT06017037 / RecruitingPhase 1/2IIT

REward Processing And Citalopram Study

The goal of this experimental medicine study is to examine the effect of increasing serotonin on reward processing in healthy volunteers. The main questions it aims to answer are:
1. Does a subacute increase in serotonin influence the activation regions during reward learning
2. Does a subacute increase in serotonin influence behavioural markers of reward valuation (effort task), responsiveness (taste task) and learning (learning task)
Participants will be:
given a 7-day course of the selective serotonin reuptake inhibitor, citalopram. undergo behavioural testing complete a reward learning task whilst undergoing fMRI
Researchers will compare results against a placebo group.

Start Date19 May 2023

Sponsor / Collaborator

University of Oxford

CTR20223073 / CompletedNot Applicable

氢溴酸西酞普兰片（20mg）健康人体生物等效性研究

[Translation] Bioequivalence Study of Citalopram Hydrobromide Tablets (20mg) in Healthy Humans

以药代动力学参数作为主要终点评价指标，分别比较在空腹/餐后状态下口服受试制剂氢溴酸西酞普兰片（生产厂家：昆明积大制药股份有限公司）与参比制剂氢溴酸西酞普兰片（持证商：H. Lundbeck A/S 丹麦灵北药厂，商品名：喜普妙®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂氢溴酸西酞普兰片和参比制剂氢溴酸西酞普兰片在健康受试者中的安全性。

[Translation]

Taking pharmacokinetic parameters as the primary endpoint evaluation indicators, the test preparation citalopram hydrobromide tablets (manufacturer: Kunming Jida Pharmaceutical Co., Ltd.) and the reference preparation hydrobromide were compared respectively under fasting/fed state. Pharmacokinetic behavior of citalopram tablets (license holder: H. Lundbeck A/S Danish Lundbeck Pharmaceutical Factory, trade name: Xipumi®) in healthy subjects, and the biological evaluation of the two preparations was evaluated. equivalence. Secondary purpose: To observe the safety of the test preparation citalopram hydrobromide tablets and the reference preparation citalopram hydrobromide tablets in healthy subjects.

Start Date01 Dec 2022

Sponsor / Collaborator

Kunming Jida Pharmaceutical Co. Ltd.

CTR20222823 / CompletedNot Applicable

健康受试者空腹/餐后条件下单次口服氢溴酸西酞普兰片的单中心、随机、开放、两序列、两周期、交叉生物等效性试验

[Translation] A single-center, randomized, open-label, two-sequence, two-cycle, crossover bioequivalence trial of a single oral dose of citalopram hydrobromide tablets in healthy subjects under fasting/postprandial conditions

主要目的：考察健康受试者在空腹/餐后条件下单剂量口服氢溴酸西酞普兰片（规格：20mg）后的体内药代动力学特征，评价受试制剂（T）与参比制剂（R）的生物等效性。次要目的：评价单剂量口服氢溴酸西酞普兰片（规格：20mg）受试制剂及参比制剂在中国健康受试者中的安全性。

[Translation]

Main purpose: To investigate the in vivo pharmacokinetic characteristics of healthy subjects after taking a single dose of citalopram hydrobromide tablets (specification: 20 mg) under fasting/postprandial conditions, and to evaluate the test preparation (T) and the reference preparation (R) Bioequivalence. Secondary objective: To evaluate the safety of single-dose oral citalopram hydrobromide tablets (strength: 20 mg) of the test preparation and reference preparation in healthy Chinese subjects.

Start Date04 Nov 2022

Sponsor / Collaborator

Sichuan Beiling Heyi Pharmaceutical Co., Ltd.

100 Clinical Results associated with Citalopram Hydrobromide

100 Translational Medicine associated with Citalopram Hydrobromide

100 Patents (Medical) associated with Citalopram Hydrobromide

126

Literatures (Medical) associated with Citalopram Hydrobromide

01 May 2024·Otolaryngology–Head and Neck Surgery

Olfactory‐Related Adverse Events: An Analysis of the Food and Drug Administration Adverse Events Reporting System

Article

Author: Minutello, Katrina M ; Hasan, Md Sakibur ; Emmer, Eriel ; Lenkeit, Christopher P ; Santiago Rivera, Olga ; Lofgren, Daniel H ; Downs, Asha

AbstractObjectiveOlfactory dysfunction has gained considerable interest with its association to the coronavirus pandemic. Due to the limited literature on olfactory‐related adverse events (ORAE) associated with medications, this study investigated ORAE reported in the Food and Drug Administration Adverse Event Reporting System (FAERS) to identify the most frequent medications associated with these reactions.Study DesignCross‐sectional analysisSettingFAERS database.MethodsThe FAERS database was accessed to obtain ORAEs from 2012 to 2022. Disproportionality analysis was conducted by calculating the proportional reporting ratios (PRR) and reporting odds ratio (ROR) for anosmia, parosmia, hyposmia, and olfactory dysfunction. A PRR > 2 or ROR > 1 was significant. A multivariate logistical model was used to estimate adjusted ROR for gender and country of origin.ResultsOur final study population consisted of 1111 cases with the following symptoms: anosmia (672), parosmia (364), hyposmia (71), and olfactory dysfunction (4). The most significant ROR signal scores were found for secukinumab (3.42; 95% confidence interval, CI [1.9, 4.01]) for anosmia, levofloxacin (8.86; 95% CI [2.83, 9.8]) for hyposmia, and pregabalin (6.88; 95% CI [2.23, 8.01]) for parosmia. No significant PRR signal scores were found for anosmia, but significant signals were found for citalopram hydrobromide (17.25; 95% CI [17.01, 17.49]) in hyposmia, and dimethyl fumarate (3.18; 95% CI [3.09, 3.27]) in parosmia. No valid PRR or ROR values were found for olfactory dysfunction. Multivariate analysis did not reveal statistically significant differences between genders for any symptoms, but individuals from non‐US countries did exhibit statistically significant elevated risk of anosmia (1.3 (95% CI [1.01, 1.68]).ConclusionPharmacovigilance studies provide an opportunity to evaluate the safety profile of medications regarding ORAE, particularly for those commonly prescribed for sinonasal symptoms. Findings from this study may function as a resource for prescribers and patients.

27 Oct 2023·ACS sensors

Toward Personalized Treatment of Depression: An Affordable Citalopram Test based on a Solid-Contact Potentiometric Electrode for at-Home Monitoring of the Antidepressant Dosage.

Article

Author: Ong, Victor ; Chen, Ruitong ; Ma, Haozheng ; Amirghasemi, Farbod ; Tran, Ava ; Mousavi, Maral P S

Citalopram (CTLP) is one of the most common antidepressants prescribed worldwide. It has a narrow therapeutic window and can cause severe toxicity and mortality if the dosage exceeds the safe level. Reports indicated that at-home monitoring of citalopram dosage considerably benefits the patients, yet there are no devices capable of such measurement of citalopram in biofluids. This work presents an affordable citalopram test for at-home and point-of-care monitoring of citalopram levels in urine, ensuring a safe and effective drug compliance. Our platform consists of a citalopram-selective yarn-based electrode (CTLP-SYE) that uses polymeric sensing membranes to provide valuable information about drug concentration in urine. CTLP-SYE is noninvasive and has a response time of fewer than 10 s. The fabricated electrode showed near-Nernstian behavior with a 52.3 mV/decade slope in citalopram hydrobromide solutions ranging from 0.5 μM to 1.0 mM, with a detection limit of 0.2 μM. Results also indicated that neither interfering ions nor pH affects electrode performance. We showed that CTLP-SYE could accurately and reproducibly measure citalopram in human urine (RSD 2.0 to 3.2%, error <12%) at clinically relevant concentrations. This work paves the way for the personalized treatment of depression and accessible companion diagnostics to improve treatment efficacy and safety.

01 May 2023·Environmental Toxicology and Chemistry

Investigating Population‐Level Toxicity of the Antidepressant Citalopram in Harpacticoid Copepods Using In Vivo Methods and Bioenergetics‐Based Population Modeling

Article

Author: De Schamphelaere, Karel A C ; Koch, Josef

AbstractRecent research has revealed various lethal and sublethal effects of the selective serotonin reuptake inhibitor citalopram hydrobromide on the harpacticoid copepod Nitocra spinipes. In the present study, an individual‐based model (IBM) grounded in the dynamic energy budget (DEB) theory was developed to extrapolate said effects to the population level. Using a generic DEB‐IBM as a template, the model was designed to be as simple as possible, keeping model components that are outside the scope of the core DEB theory to a minimum. To test the model, a 56‐day population experiment was performed at 0, 100, and 1000 μg citalopram hydrobromide L−1. In the experiment, the populations quickly reached a plateau in the control and at 100 μg L−1, which was correctly reproduced by the model and could be explained by food limitations hindering further population growth. At 1000 μg L−1, a clear mismatch occurred: Whereas in the experiment the population size increased beyond the supposed (food competition–induced) capacity, the model predicted a suppression of the population size. It is assumed that the IBM still misses important components addressing population density–regulating processes. Particularly crowding effects may have played an important role in the population experiment and should be further investigated to improve the model. Overall, the current DEB IBM for N. spinipes should be seen as a promising starting point for bioenergetics‐based copepod population modeling, which—with further improvements—may become a valuable individual‐to‐population extrapolation tool in the future. Environ Toxicol Chem 2023;42:1094–1108. © 2023 SETAC

News (Medical) associated with Citalopram Hydrobromide

08 Nov 2023

·www.biospace.com

As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)

Company Introduces Multimedia Resources to Bring Awareness of SAD LAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving time concluded for much of the US on November 5, and as the seasons change and the days grow shorter, many people may find themselves grappling with the onset symptoms of seasonal affective disorder (SAD). SAD is a type of depression that follows a seasonal pattern and most often occurs with the change to the fall-winter season. Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC), a global diversified pharmaceutical company dedicated to advancing global health, is helping to raise awareness about the importance of SAD symptom recognition and dialogue with a healthcare professional. Specifically, Bausch Health has introduced several comprehensive initiatives to raise awareness for SAD symptoms and prevention, including a national television ad for its antidepressant APLENZIN® (bupropion hydrobromide) extended-release tablets, the only FDA-approved bupropion hydrobromide that is indicated for the prevention of SAD. The campaign is designed to inform individuals about SAD symptoms during the autumn and winter months and to encourage people diagnosed with SAD to engage in a dialogue with a healthcare professional about potential prevention and treatment-related strategies as needed. "SAD is a seasonal type of depression that manifests itself in the fall and winter months. When there's less sunlight outside, a person's natural ability to regulate certain chemicals can be disrupted which may impact depression," said Eric Guenin, PharmD, Ph.D., MPH, executive director, medical affairs, Bausch Health. "Prevention is key, when possible, so people must be aware of some of the symptoms of SAD, such as feeling depressed most of the day almost every day, losing interest in activities they once enjoyed, experiencing low energy, facing difficulty sleeping, weight changes, and be encouraged to discuss them with a healthcare professional as preventive treatment options exist." In addition to the ad campaign, there is a revamped APLENZIN website, which features a SAD fact sheet as well as a new patient engagement program called "Real Talk with APLENZIN" that provides subscribers with helpful tools and support. The site also includes a downloadable health questionnaire and "mood tracker" that provides patients practical tools to share and discuss with a healthcare professional, who can determine if there is a seasonal pattern to their symptoms. To learn more about APLENZIN please see Important Safety Information including boxed warning below and visit . About SAD SAD is a type of depression that follows a seasonal pattern. Symptoms often occur during the fall and winter months. SAD is more than the "winter blues," it is a serious mental health condition. When there's less sunlight outside, a person's natural ability to regulate certain chemicals can be disrupted which may impact depression. And that may lead to symptoms of SAD. The seasonal symptoms of SAD can include but are not limited to feeling depressed most of the day, nearly every day; losing interest in activities you once enjoyed; feeling hopeless or worthless; withdrawing socially; overeating, particularly craving carbohydrates; weight gain; and oversleeping. About APLENZIN APLENZIN (bupropion hydrobromide) is an antidepressant indicated for the treatment of major depressive disorder and prevention of SAD. APLENZIN is the only FDA-approved bupropion hydrobromide and offers extensive clinical experience in patients with MDD or SAD. APLENZIN is a once-daily, single tablet available in 3 dosage strengths, with no generic substitute. Recommended dosing for patients with SAD includes initiating treatment in the fall and discontinuing in early spring, as prescribed by a healthcare professional. For more information, visit . INDICATION APLENZIN® (bupropion hydrobromide extended-release tablets) is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder, and for the prevention of autumn-winter seasonal depression (seasonal affective disorder). IMPORTANT SAFETY INFORMATION WARNING: CHANGES IN THINKING AND BEHAVIOR, DEPRESSION, AND SUICIDAL THOUGHTS OR ACTIONS Suicidal Thoughts or Actions and Antidepressant Drugs Antidepressants may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. People who have (or have a family history of) bipolar illness or suicidal thoughts or actions may have a particularly high risk. Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if symptoms such as anxiety, irritability, impulsivity, trouble sleeping, aggressive behavior or suicidal thoughts are new, worse or worry you. APLENZIN has not been evaluated for use in patients under the age of 18. Call your healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling very agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood Although APLENZIN is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking. Some people have had serious side effects while taking bupropion to help them quit smoking, including: New or worse mental health problems, such as changes in behavior or thinking, aggression, hostility, agitation, depression, or suicidal thoughts or actions. Some people had these symptoms when they began taking bupropion, and others developed them after several weeks of treatment, or after stopping bupropion. These symptoms happened more often in people who had a history of mental health problems before taking bupropion than in people without a history of mental health problems. Stop taking APLENZIN and call your healthcare provider right away if you, your family, or caregiver notice any of these symptoms. Work with your healthcare provider to decide whether you should continue to take APLENZIN. In many people, these symptoms went away after stopping APLENZIN, but in some people, symptoms continued after stopping APLENZIN. It is important for you to follow-up with your healthcare provider until your symptoms go away. Before taking APLENZIN, tell your healthcare provider if you have ever had depression or other mental health problems. You should also tell your healthcare provider about any symptoms you had during other times you tried to quit smoking, with or without bupropion. What Other Important Information Should I Know About APLENZIN? Seizures: There is a chance of having a seizure (convulsion, fit) with APLENZIN, especially in people with certain medical problems or who take certain medicines. Do not take any other medicines while you are taking APLENZIN unless your healthcare provider has said it is okay to take them. If you have a seizure while taking APLENZIN, stop taking the tablets and call your healthcare provider right away. High blood pressure (hypertension): Some people get high blood pressure that can be severe while taking APLENZIN. Manic episodes: Some people may have periods of mania while taking APLENZIN. If you have any of the following symptoms of mania, call your healthcare provider: greatly increased energy severe trouble sleeping racing thoughts reckless behavior unusually grand ideas excessive happiness or irritability talking more or faster than usual Unusual thoughts or behaviors: Some patients may have unusual thoughts or behaviors while taking APLENZIN, including delusions (e.g., believe you are someone else), hallucinations (seeing or hearing things that are not there), paranoia (feeling that people are against you), or feeling confused. If this happens to you, call your healthcare provider. Visual problems: Some people are at risk of glaucoma which can present as: eye pain, changes in vision, or swelling and redness around the eye if they take APLENZIN. You should see an eye doctor to determine whether you are at risk prior to starting therapy. Severe allergic reactions: Some patients have severe allergic reactions to APLENZIN. Stop taking APLENZIN and call your healthcare provider right away if you get a rash, itching, hives, fever, swollen lymph glands, painful sores in the mouth or around the eyes, swelling of the lips or tongue, chest pain, or have trouble breathing. These could be signs of a serious allergic reaction. Do not take APLENZIN if you: have or had a seizure disorder or epilepsy have or had an eating disorder such as anorexia nervosa or bulimia are taking any other medicines that contain bupropion, including WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, ZYBAN, or FORFIVO XL. Bupropion is the same active ingredient that is in APLENZIN drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these make you sleepy), benzodiazepines, or anti-seizure medicines, and you stop using them all of a sudden take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid do not take an MAOI within 2 weeks of stopping APLENZIN unless directed to do so by your healthcare provider do not start APLENZIN if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your healthcare provider are allergic to the active ingredient in APLENZIN, bupropion, or to any of the inactive ingredients Although APLENZIN is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking. Before taking APLENZIN, tell your healthcare provider if you have ever had depression, suicidal thoughts or actions, or other mental health problems or any symptoms you had during other times you tried to quit smoking with or without bupropion. Also, tell your healthcare provider about your other medical conditions, including if you: have liver problems, especially cirrhosis of the liver have kidney problems have, or have had, an eating disorder such as anorexia nervosa or bulimia have had a head injury have had a seizure (convulsion, fit) have a tumor in your nervous system (brain or spine) have had a heart attack, heart problems, or high blood pressure are a diabetic taking insulin or other medicines to control your blood sugar drink alcohol abuse prescription medicines or street drugs are pregnant or plan to become pregnant. Talk to your healthcare provider about the risk to your unborn baby if you take APLENZIN during pregnancy, and about registering with the National Pregnancy Registry by calling 1-844-405-6185 are breastfeeding. APLENZIN passes into your milk in small amounts Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Many medicines increase your chances of having seizures or cause other serious side effects if you take them while you are using APLENZIN. The most common side effects of APLENZIN include: trouble sleeping, stuffy nose, dry mouth, dizziness, feeling anxious, nausea, constipation, and joint aches. Click here to read the Medication Guide carefully before you start using APLENZIN. If you have any questions about APLENZIN, ask your healthcare provider or pharmacist. Click here for full Prescribing Information, including Medication Guide and Boxed Warning regarding suicidal thoughts and actions. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also contact Bausch Health Customer Service at 1-800-321-4576. About Bausch Health Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit and connect with us on Twitter and LinkedIn. Media Contact: Kevin Wiggins corporate.communications@bauschhealth.com (908) 541-3785 Investor Contact: ir@bauschhealth.com (908) 541-2102 (877) 281-6642 (toll free) References Hansen BT, et al. Daylight Savings Time Transitions and the Incidence Rate of Unipolar Depressive Episodes. Epidemiology. 2017;28(3):346-353. American Psychiatric Association. Seasonal affective disorder (SAD). . Accessed September 1, 2022. Meesters Y, Gordijn MCM. Seasonal affective disorder, winter type: current insights and treatment options. Psychol Res Behav Manag. 2016;9:317-327. National Institute of Mental Health. Seasonal affective disorder. . Accessed September 1, 2022. APLENZIN (bupropion hydrobromide extended-release) Prescribing Information. Bausch Health Companies Inc. Melrose S. Seasonal affective disorder: an overview of assessment and treatment approaches. Depress Res Treat. 2015;2015:178564. APLENZIN is a trademark of Bausch Health Companies Inc. or its affiliates. Any other product/brand names and/or logos are trademarks of the respective owners. © 2023 Bausch Health Companies Inc. or its affiliates. APL.0132.USA.23 SOURCE: Bausch Health Companies Inc. View source version on accesswire.com:

Drug Approval

13 Sep 2023

·www.prnewswire.com

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 mg Tablets (generic name: peficitinib hydrobromide) in Taiwan for the treatment of rheumatoid arthritis. Smyraf® has been approved in Taiwan and has patent protection for composition of matter until 2032. Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments. In addition, Menarini will pay Astellas a high-single digit percentage royalties on net sales of Smyraf®. Menarini will have an option to extend the rights to select South-East Asian markets. Smyraf® was developed and is currently marketed in Japan by Astellas and is indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have an inadequate response to conventional therapies. Rheumatoid arthritis (RA) is a chronic autoimmune disorder that primarily affects the joints, causing inflammation, pain, and potential joint damage. With an estimated prevalence of 287.0 per 100,000 persons in Taiwan[1], rheumatoid arthritis is acknowledged as a significant health problem, and efforts are being made to enhance its diagnosis, treatment, and management amidst an ageing population in the region. "Menarini has a long history as the partner of choice for many biopharmaceutical companies across the Asia-Pacific region and we are excited that Astellas has trusted Menarini to promote and commercialize Smyraf®. Patients suffering from rheumatoid arthritis often need different options if the treatment target is not achieved. With proven efficacy and flexible dosing benefits, Smyraf® will play an important role in this regard," said Maurizio Luongo, Chief Executive Officer of Menarini Asia-Pacific. [1]{Global Burden of Disease Collaborative Network}. 2020. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle. USA. {Institute for Health Metrics and Evaluation (IHME)}. / About Menarini Asia-Pacific Menarini Asia-Pacific is a member of the Menarini Group, the world's largest Italian biopharmaceutical company with a heritage of over 130 years and over 17,000 employees in more than 140 countries. Here in Asia-Pacific, Menarini's vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval, and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men's Health. For the Financial Year 2022, the Menarini Group's revenue registered 4.15 billion euros, of which the Asia Pacific region has grown to become a dynamic engine of growth for the Group with more than 10% revenue contribution. For more information, visit Logo - SOURCE Menarini Asia-Pacific

License out/inDrug Approval

26 Jul 2023

·www.prnewswire.com

Obsessive-Compulsive Disorder (OCD) Industry Report 2023: Treatment Landscape Reveals Promising Prospects for Improved Patient Outcomes

DUBLIN, July 26, 2023 /PRNewswire/ -- The "Obsessive-Compulsive Disorder (OCD) Market Insights, Epidemiology, and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. Obsessive-Compulsive Disorder (OCD) Market: In-Depth Analysis and Treatment Landscape Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by intrusive thoughts, images, or impulses causing anxiety, and repetitive behaviors aimed at reducing that anxiety. It follows a chronic course, often leading to years of suffering before seeking treatment. The DSM-5 diagnostic criteria for OCD remain largely unchanged from DSM-IV, with two specifiers added: insight and tic-related disorder. Market Overview: In 2022, there were approximately 12,082,000 total prevalent cases of OCD in the 7 major markets (7MM). Most diagnosed cases are severe, with 50% classified as severe, 35% as moderate, and 15% as mild. The United States accounted for the highest number of diagnosed cases in 2022, approximately 2,156,000 cases, and the OCD market size in the US was around USD 600 million. Treatment Landscape: Treatment for OCD involves building a therapeutic alliance, psychoeducation, and utilizing psychological and/or pharmacological approaches. Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed medications for OCD, with drugs like sertraline, fluoxetine, and fluvoxamine being popular choices. Emerging Therapies: Troriluzole, developed by Biohaven Pharmaceuticals, is a promising drug in the OCD treatment landscape. It is a glutamate-release inhibitor and has shown encouraging results in clinical trials. If successful, troriluzole is expected to bring major changes in the OCD treatment landscape, offering safer and more effective options. Market Outlook: The total market size of OCD in the 7MM is projected to increase at a CAGR of ~5%, reaching approximately USD 1,000 million by 2032. The growth is driven by an increase in the prevalent pool of the disease and the launch of new therapies. Key Highlights: Obsessive-compulsive disorder (OCD) has been given increased attention in DSM-5, receiving its chapter. However, the diagnostic criteria for OCD in DSM-5 remain largely the same as in DSM-IV, requiring either obsessions or compulsions. The major change in the DSM-5 criteria for OCD is the addition of two specifiers for this diagnosis: insight and tic-related disorder. OCD symptoms may be present for years before treatment is sought, and those affected often suffer in silence. The disease follows a chronic waxing and waning course where 15% of patients have deterioration, and 5% have episodes with inter-episode recovery. The diagnosis of obsessive-compulsive disorder (OCD) is established by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria, while the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is used for the assessment of its severity. In 2022, there were ~12,082,000 total prevalent cases of obsessive-compulsive disorder (OCD) in the 7MM. Most of the diagnosed cases of Obsessive Compulsive Disorder (OCD) are severe, with around 15%, 35%, and 50% of individuals having mild, moderate, and severe OCD, respectively. The United States accounted for the highest number of diagnosed cases of OCD in the 7MM, i.e., ~2,156,000 cases in 2022. In 2022, the market size of OCD was the highest in the US among the 7MM, accounting for approximately USD 600 million. Treatment of OCD comprises several components, starting with building a therapeutic alliance with the patient and psychoeducation. Then psychological and/or pharmacological approaches, and, for patients with treatment-resistant OCD, neuromodulation, and neurosurgery. The NICE guidelines propose CBT as the treatment of choice for OCD and body dysmorphic disorder due to the rigorous research invested into CBT for OCD and the effectiveness of treatment. The expected launch of troriluzole (Biohaven Pharmaceuticals) by 2027 is set to bring major changes in the treatment landscape of OCD, bringing in safer and more effective treatment options for OCD patients. Selective Serotonin Reuptake Inhibitors (SSRIs) are the most popular form of treatment for OCD, which works by increasing serotonin levels in the brain. Some widely used medications for the treatment of OCD are citalopram (CELEXA, CIPRAMIL), escitalopram (CIPRALEX, LEXAPRO), fluoxetine (PROZAC), fluvoxamine (FAVERIN, LUVOX), paroxetine (PAXIL, SEROXAT), sertraline (LUSTRAL, ZOLOFT). If these medications fail to work, a non-selective SRI may be prescribed. However, because it affects neurotransmitters in the brain other than just serotonin, there are more side effects, and therefore it is usually not a first-choice medication for treating OCD. The non-selective SRI most commonly used for treating OCD is clomipramine (ANAFRANIL). The generic alternatives of the approved marketed assets for OCD, such as sertraline hydrochloride, fluoxetine, fluvoxamine, clomipramine, etc., entered the market from 1996-2006. Key Topics Covered 1. Key Insights 2. Report Introduction 3. OCD Market Overview at a Glance 4. Executive Summary of Obsessive-compulsive Disorder (OCD) 5. Epidemiology and Market Methodology 6. Disease Background and Overview 7. Epidemiology and Patient Population 8. Patient Journey 9. Marketed Therapies 10. Emerging Therapies 11. OCD: The 7MM Market Analysis 12. KOL Views 13. SWOT Analysis 14. Unmet needs 15. Market Access and Reimbursement 16. Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Drug Approval

100 Deals associated with Citalopram Hydrobromide

External Link

KEGG	Wiki	ATC	Drug Bank
D00822	Citalopram Hydrobromide	N06AB04	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder, Major	US	ALMATICA PHARMA INC	31 Jan 2022
Depressive Disorder	DK	H. Lundbeck A/S	01 Jan 1989

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	Discovery	RU	Kalaco Scientific, Inc.	01 Oct 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01189812 (CTgov)	Phase 2	Borderline Personality Disorder \| Depressive Disorder, Major	80	Lithium Carbonate+citalopram	loknaocbrt(ufzytnjgkr) = uekoqgnyln rszkkwudfj (ykeahjencf, ivbhsyvxpy - djtiyseegf) View more	-	08 Jun 2011
NCT00962039 (CTgov)	Phase 2/3	Anxiety \| Abdominal Pain	81	citalopram (Citalopram)	guqqudhdeo(jyzahjmyst): Mean Difference (Net) = -0.01 (95% CI, -0.12 to 0.10) View more	-	11 Jun 2020
				Placebo (Placebo)
NCT00930293 (CTgov)	Not Applicable	Panic \| Depressive Disorder \| Depression \| Anxiety	50	Interpersonal Psychotherapy for Depression+Citalopram hydrobromide (Personalized Depression Care)	qxpxjkehez(bbsgwwmigd) = ewryvcaqwo algegkmoqy (cutkskaqyd, nbvtcxmfcv - lahbdlngiu) View more	-	09 Feb 2016
				Brief Supportive Psychotherapy (BSP)+Citalopram hydrobromide (Standard Depression Care)	qxpxjkehez(bbsgwwmigd) = dapmlumomj algegkmoqy (cutkskaqyd, kiwcgoqzai - inorhynkcp) View more
NCT00271596 (CTgov)	Phase 2	Huntington Disease \| Hodgkin's Lymphoma \| Impairment of Executive Functions	33	20mg daily citalopram (Citalopram)	jpvssldvup(lfzxmkdiir) = erkgjvyzli swozesgojz (adaiftwkuh, ebdyaabqzg - yggasghyyn) View more	-	13 Mar 2013
				Placebo (Placebo)	jpvssldvup(lfzxmkdiir) = dlgveltwkm swozesgojz (adaiftwkuh, hixlixazfk - gpuyynolzm) View more
NCT00129467 (CTgov)	Not Applicable	Behavioural disorders \| Neoplasms \| Depressive Disorder	47	Methylphenidate+Selective Serotonin Uptake Inhibitor (SSRI) (Methylphenidate + SSRI)	ppwkawklxa(uuquyaulwr) = kihjelyent brvrozxmqp (ehqiqzwdyg, pkckmnzrwr - dlkslrdlpx) View more	-	12 Feb 2014
				Placebo+Selective Serotonin Uptake Inhibitor (SSRI) (Placebo + SSRI)	ppwkawklxa(uuquyaulwr) = gunjfutezv brvrozxmqp (ehqiqzwdyg, xqujuoovoh - ezufcsyuss) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis